NCT05393895View on ClinicalTrials.gov

An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
Presbyopia
Interventions
DRUG

CSF-1

One drop bilaterally twice daily for at least 6 weeks

DRUG

Vehicle

One drop bilaterally twice daily for at least 6 weeks

Trial Locations (12)

16066

Orasis Investigative Site, Cranberry Township

18704

Orasis Investigative Site, Kingston

27909

Orasis Investigative Site, Elizabeth City

38119

Orasis Investigative Site, Memphis

58103

Orasis Investigative Site, Fargo

61201

Orasis Investigative Site, Rock Island

66210

Orasis Investigative Site, Overland Park

78613

Orasis Investigative Site, Cedar Park

80907

Orasis Investigative Site, Colorado Springs

92663

Orasis Investigative Site, Newport Beach

94954

Orasis Investigative Site, Petaluma

06810

Orasis Investigative Site, Danbury

Sponsors
All Listed Sponsors
lead

Orasis Pharmaceuticals Ltd.

INDUSTRY